Navigation Links
Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
Date:9/20/2011

o fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to maintain the company's investment grade credit ratings with the ratings agencies; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; reductions in asset valuations and related impairment charges; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Isis Forward Looking Statement

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, and the therapeutic and commercial potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered
'/>"/>

SOURCE BioMed Realty Trust, Inc.; Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
(Date:9/22/2014)... , Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... scheduled to present a corporate overview and update at ... September 26, 2014, at 11:30 a.m. Eastern Time (8:30 ... New York City . ... available under the investor relations section of Arena,s website ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
(Date:9/22/2014)... out to be an old acquaintance: a certain module ... been considered an anchor protein. The researchers report their ... Essential: importing enzymes into peroxisome , Peroxisomes are ... fatty acids and cellular toxins. In order for them ... be imported into the peroxisomes first. The bulk is ...
(Date:9/22/2014)... of more than 30,000 nurses across Europe show that ... more likely to rate the standard of care delivered ... of their hospitals safety and omit necessary patient care. ... and the National Nursing Research Unit (NNRU) at King,s ... 450 hospitals across 12 European countries, was part of ...
(Date:9/22/2014)... Following 14 months of field ... Clearwater Clinical announced the general release of ... for smartphones. ClearSCOPE enables health professionals to capture ... and smartphone. , ENT and Urology specialists developed ... over the cost, encumbrance and slow innovation cycle ...
(Date:9/22/2014)... Thousand Oaks dentist , Dr. Sharon ... Invisalign is a type of orthodontic treatment that can ... can vary based on the extent of the dental ... needed. During this promotion, Dr. Shamoiel is offering complete ... of the adult population has an unhealthy bite, and ...
(Date:9/22/2014)... The invitation only Summit held ... 60 industry executives and thought leaders from major ... Retro Fitness, and Xsport Fitness. Also in attendance ... marketing agencies and private equity investors representing over ... , The Summit highlighted best practices for solving ...
Breaking Medicine News(10 mins):Health News:The accelerator of molecular motors 2Health News:Nurse survey shows longer working hours impact on quality of care 2Health News:ClearSCOPE 2.0 Endoscope Adaptor for Smartphones Announced; Endoscopic Video Capture Reinvented 2Health News:Thousand Oaks Cosmetic Dentist, Sharon Shamoiel DDS, Is Now Offering a Special on Invisalign 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 2Health News:Motionsoft Concludes Inaugural 2014 Technology Summit 3
... ARBOR, Mich.---Scientists have discovered a molecular assistant called Spy that ... purposes. Bacteria are widely used to manufacture proteins used ... job. Many proteins fall apart and get cut up inside ... useless tangles instead of folding properly, as they must in ...
... FL 14 February, 2011 Elsevier / MEDai, ... announced today the launch of the latest version of ... The new version will feature an expanded set of ... new predictions: ICU Admission Prediction, Length of Stay Prediction ...
... two pesticides, rotenone and paraquat, and Parkinson,s disease. People ... times more often than non-users. The study ... National Institute of Environmental Health Sciences (NIEHS), which is ... Parkinson,s Institute and Clinical Center in Sunnyvale, Calif. ...
... 11 (HealthDay News) -- The U.S. Food and Drug ... that provides three-dimensional images of the breast for cancer ... an upgrade to Massachusetts-based Hologic Inc.,s FDA-approved two-dimensional system, ... breasts. The 3-D images may help physicians more accurately ...
... , SUNDAY, Feb. 13 (HealthDay News) -- People who ... may be protecting themselves from developing Parkinson,s disease, a ... are found in a variety of foods such as ... touted as protective against some diseases because of their ...
... News) -- Hunters who use tree stands can stay safe ... a study on tree stand safety. The reminder comes ... from tree stands and four died during the recent deer-hunting ... falls in Alabama in a single year, said the state,s ...
Cached Medicine News:Health News:Quest for designer bacteria uncovers a 'Spy' 2Health News:Elsevier/MEDai enhances real-time clinical surveillance system for hospitals 2Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:FDA Approves First 3D Mammogram Device 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Spate of Hunter Injuries Spurs New Call for Tree Stand Safety 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: